We are Healthy
World

HIV Mutations Let Virus Escape Key Antibody

Adults in HIV prevention research learn that VRC01 offered partial protection but did not prevent infection overall, pointing to antibody combinations.

Updated on Nov. 6, 2026 in Diseases — General

Single glass microscope slide with a faint pale smear on a grey laboratory bench under soft daylight, with out-of-focus pipette tips in the background.
Researchers found HIV can mutate to escape the antibody VRC01, which offered partial protection in a 4,600-participant prevention trial but did not prevent infection overall. AI Illustration. Upload story photo >

Researchers found that HIV can develop mutations that let it escape VRC01, an antibody tested in prevention trials involving more than 4,600 participants. The study, published in Nature Microbiology, suggests newer antibodies may still work against these escaped viruses.

Why it matters

VRC01 gave about 75% protection against viruses highly sensitive to the antibody, but it did not prevent HIV infections overall, so understanding how the virus escapes shapes which prevention approaches are pursued next. The findings matter now because they explain a gap in the trial results and point toward combinations of antibodies as a way to limit the virus's options.

Researchers analysed 11,730 HIV genetic sequences from 47 trial participants using deep sequencing, comparing 26 VRC01 recipients with 21 placebo recipients. Eight VRC01 recipients developed resistance-associated mutations, and the mutations identified were rare among HIV viruses circulating globally.

The players

University of Cape Town

A South African university whose researchers led the study of HIV antibody escape.

University of the Witwatersrand

A South African university whose researchers contributed to the sequencing and analysis of the trial data.

The details

Deep sequencing detects rare variants within the HIV viral population, allowing researchers to spot mutations that were present at low levels before they became dominant. The AMP trial underestimated the antibody dose needed to block HIV acquisition, which gave the virus a window to escape. Newer antibodies N6 and 1-18 largely retained the ability to neutralise viruses that had escaped VRC01.

Timeline

  1. Study published in Nature Microbiology on November 5, 2026.

Health Landscape

The AMP trials of VRC01 showed that broadly neutralising antibodies can offer partial protection against HIV, but they did not prevent infection overall. This study adds evidence on how the virus escapes such antibodies, which informs the design of future prevention strategies.

For people following HIV prevention research, this study shows that antibody-based approaches are still being refined and are not yet a standalone shield. Anyone with questions about HIV prevention options should discuss them with a clinician.

The takeaway

Antibody-based HIV prevention is still being studied, and combinations of antibodies may limit the virus's ability to escape. Anyone weighing HIV prevention options should talk with a healthcare provider about what is currently available.

Further reading

For broader context on HIV and other conditions, explore the Diseases — General section.

Source note: This article includes information reported by Uct.